<DOC>
	<DOCNO>NCT00462761</DOCNO>
	<brief_summary>Patients receive oral AC220 daily 14 day study side effect , tolerability best dose treat relapsed refractory acute myeloid leukemia , regardless FLT3 status .</brief_summary>
	<brief_title>A Phase I Study AC220 Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless FLT3 Status</brief_title>
	<detailed_description>This multi-center clinical study conduct USA possibly two international site . It open-label , dose escalation study design characterize safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) orally administer AC220 single agent give daily 14 day . Cohorts 3 patient receive AC220 dose limit toxicity note ( DLT ) . At point cohort expand 6 patient MTD determine . Patients experience DLT significant disease progression Day 15 may continue receive AC220 discretion Investigator Sponsor . FLT3 positive negative patient allow participate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>1 . Males females age ≥ 18 year ; 2 . Histopathologically documented primary secondary AML , define WHO criteria ( Jaffe et al , 2001 ) , confirm pathology review treat institution , meet least one following : 1 . Refractory least 1 cycle induction chemotherapy , 2 . Relapsed least 1 cycle induction chemotherapy , 3 . Patient , accord clinical judgment Principal Investigator , candidate induction chemotherapy due age , comorbidity , factor ; 3 . Patients standard therapy anticipate result durable remission , fail potentially curative therapy , refuse standard therapy patient know therapy document treatment benefit ; 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 03 ; 5 . In absence rapidly progress disease , interval prior treatment time AC220 administration least 2 week cytotoxic agent ( hydroxyurea , per Section 8.8 ) , least 5 halflives noncytotoxic agent ; 6 . Persistent chronic clinically significant toxicity prior chemotherapy surgery must less Grade 2 ; 7 . Serum creatinine ≤ 2.0 mg/dL ; 8 . Total serum bilirubin ≤ 1.5 × ULN unless consider due Gilbert 's syndrome leukemic organ involvement ; 9 . Serum AST ALT ≤ 3.0 × ULN unless consider due leukemic organ involvement ; 10 . Females childbearing potential must negative pregnancy test ( urine βhCG ) ; 11 . Females childbearing potential sexually mature male must agree use medically accept method contraception throughout study ; 12 . Written informed consent must provide . 1 . Histologic diagnosis acute promyelocytic leukemia ; 2 . Clinically active central nervous system leukemia ; 3 . Persistent clinically significant toxicity prior chemotherapy Grade 2 high National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE v3 ) ; 4 . Bone marrow transplant within 2 month prior study ; 5 . Active , uncontrolled infection ; 6 . Major surgery within 4 week prior study ; 7 . Radiation therapy within 4 week prior , concurrent , study ; 8 . Human immunodeficiency virus positivity ; 9 . Active hepatitis B C active liver disease ; 10 . Women pregnant , lactating , unwilling use contraception childbearing potential ; 11 . Medical condition , serious intercurrent illness , extenuate circumstance , judgment Principal Investigator , could jeopardize patient safety interfere objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>RTK</keyword>
	<keyword>kinase</keyword>
	<keyword>inhibitor</keyword>
	<keyword>tyrosine</keyword>
	<keyword>acute</keyword>
	<keyword>FLT3</keyword>
	<keyword>AC220</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>PK</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>mutation</keyword>
	<keyword>PD</keyword>
	<keyword>receptor</keyword>
	<keyword>class III</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>( 8 ; 21 )</keyword>
	<keyword>q22 ; q22</keyword>
	<keyword>AML1/ETO</keyword>
	<keyword>( 16 ; 16</keyword>
	<keyword>p13 ; q22</keyword>
	<keyword>CBFbeta/MYH11</keyword>
	<keyword>inv ( 16 )</keyword>
	<keyword>p13q22</keyword>
	<keyword>11q23</keyword>
	<keyword>dysplasia</keyword>
	<keyword>myeloid</keyword>
	<keyword>myelomonocytic</keyword>
	<keyword>monoblastic</keyword>
	<keyword>monocytic</keyword>
	<keyword>erythroid</keyword>
	<keyword>erythroleukemia</keyword>
	<keyword>megakaryoblastic</keyword>
	<keyword>basophilic</keyword>
	<keyword>panmyelosis</keyword>
	<keyword>myelofibrosis</keyword>
</DOC>